drugset / Trial / NCT01870284
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-04
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | Subcutaneous |